Use of lecithin:retinol acyl transferase gene promoter methylation in evaluating the cancer state of subject
AssigneesCornell Research Foundation, Inc., Sloan-Kettering Cancer Center, University of Medicine and Dentistry of New Jersey
InventorsFrancis Barany, Yu-Wei Cheng, Philip Paty, Daniel Notterman
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of evaluating the cancer state of a subject using lecithin:retinol acyl transferase (LRAT) gene promoter methylation status. Methods of analyzing and quantifying LRAT gene promoter methylation level are also disclosed. The present invention also relates to methods of determining the prognosis for s subject having cancer by assessing LRAT mRNA expression and LRAT protein expression. Methods of cancer detection, diagnosis, prognosis, and treatment are also disclosed.
Claims56
A method of evaluating the cancer state of a subject comprising;
- isolating a sample of DNA from a subject, and
- determining a first methylation level of the lecithin:retinol acyl transferase gene promoter nucleotide sequence, or of the region upstream of the lecithin:retinol acyl transferase gene promoter nucleotide sequence, in the DNA sample wherein the detection of a methylated lecithin:retinol acyl transferase gene promoter nucleotide sequence, or region upstream thereof, within the sample permits the evaluation of the cancer state of the subject.
A method of determining the prognosis of subject having cancer comprising:
- assessing the level of lecithin:retinol acyl transferase mRNA expression in a sample obtained from the subject and
- comparing the level of lecithin:retinol acyl transferase mRNA expression in the sample to the level of lecithin:retinol acyl transferase mRNA expression in a reference RNA standard, wherein a decrease in lecithin:retinol acyl transferase mRNA expression in the sample compared to the reference standard indicates a favorable prognosis for the subject.
A method of determining the prognosis of subject having cancer comprising:
- assessing the level of lecithin:retinol acyl transferase protein expression in a sample obtained from the subject and
- comparing the level of lecithin:retinol acyl transferase protein expression in the sample to the level of lecithin:retinol acyl transferase protein expression in a reference protein standard, wherein a decrease in lecithin:retinol acyl transferase protein expression in the sample compared to the reference standard indicates a favorable prognosis for the subject.
A method of treating a subject for cancer, said method comprising:
- treating the subject with a pharmaceutical composition which inhibits lecithin:retinol acyl transferase activity under conditions effective to treat said cancer.
Dependencies are inferred from the claim text.